Pro Football Hall of Famer and current head coach of the Colorado Buffaloes, Deion Sanders, has been declared cancer-free following a recent battle with bladder cancer.
The 57-year-old coach underwent surgery to remove his bladder after being diagnosed with an aggressive form of the disease.
The cancer was discovered during a routine check-up for previous health issues, which have included blood clots that led to the amputation of two toes in 2021. Doctors identified a tumor in his bladder and, due to its aggressive nature, recommended the removal of the organ. The surgical procedure also involved the reconstruction of a new bladder from a portion of his intestine.
Despite health concerns, Sanders will coach the Buffaloes in 2025
Despite the significant health setback, Sanders has maintained a positive outlook and has confirmed his intention to continue coaching the Buffaloes for the upcoming season. His medical team has stated that he is now cured and will not require chemotherapy or radiation. This recent health scare follows a series of circulation issues and surgeries that have plagued the iconic athlete and coach over the past few years.
While bladder cancer is less commonly diagnosed in African Americans compared to white Americans, a significant and concerning disparity exists in outcomes. African Americans are more likely to be diagnosed with advanced stages of the disease and, consequently, face higher mortality rates.
Several complex and interconnected factors contribute to this health inequity. Research points to a combination of socioeconomic and biological differences. African Americans may experience delayed diagnosis due to a variety of reasons, including reduced access to quality healthcare, lack of insurance or underinsurance, and a lower likelihood of receiving timely evaluations for early symptoms like blood in the urine (hematuria).
Systemic barriers cause African Americans to be treated later, if at all for bladder cancer
Furthermore, studies suggest that there may be differences in the biological characteristics of bladder tumors in African Americans, potentially leading to more aggressive disease. These biological variations, combined with systemic barriers to care, create a critical gap in survival rates.
For instance, even when diagnosed at the same stage, African American patients may have poorer outcomes, highlighting the need for more research into tumor biology and treatment efficacy across different ethnic groups.
The most common sign of bladder cancer is blood in the urine. Other symptoms can include frequent urination, painful urination, or a feeling of needing to urinate without being able to.
Given the disparities in outcomes, it is crucial for African Americans to be aware of these symptoms and to seek medical attention promptly. Increased awareness within the community and a commitment from the healthcare system to address and dismantle barriers to care are essential to closing the survival gap in bladder cancer.
According to the American Cancer Society, the overall 5-year relative survival rate for bladder cancer is 78%. However, when broken down by race, the 5-year relative survival rate is 78% for white people and notably lower at 65% for Black people.
A primary contributor to the higher mortality rate is the stage at which the cancer is discovered. African Americans are more frequently diagnosed with advanced, muscle-invasive bladder cancer, which is more difficult to treat successfully.
In contrast, a higher percentage of white patients are diagnosed when the cancer is at an early, non-invasive stage. For example, one report noted that 80% of Caucasian patients were diagnosed with early-stage cancer compared to 68% of African Americans.